Key result
IV ondansetron increases complete response to ~58% versus placebo in women undergoing surgery.
Why the study?
The efficacy of ondansetron in preventing postoperative nausea and vomiting in surgical patients was studied to address the need for effective prophylaxis.
Does intravenous ondansetron prevent postoperative nausea and vomiting in female surgical patients?
RCT (n=50)
Double-blind
randomized
Does intravenous ondansetron prevent postoperative nausea and vomiting in female surgical patients?
Intravenous ondansetron is highly effective in preventing postoperative nausea and vomiting in female surgical patients.
Answers are grounded in this paper and cite their sources.
Supports routine IV ondansetron use for PONV prophylaxis in women undergoing surgery; confirms efficacy versus placebo in this RCT.
The efficacy of ondansetron, a selective 5-HT3 receptor antagonist, in preventing postoperative nausea and vomiting in surgical patients was studied. Fifty women were randomized in a double-blind manner to receive either two 8 mg doses of intravenous ondansetron or two doses of placebo vehicle: the first given just before general anesthesia induction and the second 8 hours later. During the first 24 postoperative hours, the number of emetic episodes was recorded and the subjects rated their nausea on a scale from 0 to 10. Ondansetron-treated subjects had fewer emetic episodes (p less than 0.001) and lower subjective nausea scores (p less than 0.001). The number of complete responders (no emetic episodes and no rescue therapy) was 1 of 24 (4%) and 15 of 26 (58%) in the placebo and ondansetron groups, respectively (p less than 0.001). Ondansetron is clearly more effective than placebo in the prophylaxis of postoperative nausea and vomiting. The adverse event profile for ondansetron was similar to that of placebo.
No takes yet. Share an insight, caveat, or question.
Dershwitz et al. (1992) conducted an RCT in Postoperative nausea and vomiting (n=50). Ondansetron vs. Placebo was evaluated on Complete responders (no emetic episodes and no rescue therapy) (p=<0.001). Intravenous ondansetron increased the rate of complete responders (no emetic episodes or rescue therapy) compared to placebo in women undergoing surgery.
Synapse has enriched 10 related papers. Consider them for comparative context: